Case Studies
Each case study highlights a real client challenge, our approach, and the outcome delivered. Every project is led by relevant scientific expertise and shaped in close collaboration with the client team — combining rigorous thinking, practical execution, and the smart use of technology.
10+
Years of expertise
50+
Clients
10+
Therapeutic areas
By Team
All
Medical Affairs
Market Access
Brand & Launch
Regional Teams
By Expertise
All
Access / Localization
Launch support
Evidence generation
KOL / Expert engagement
Congress & Publications
Omnichannel Content
Literature & Monitoring
By TA
All
Oncology
Cardiology
Rare Disease
Immunology
Endocrinology
Infectious Diseases
Gynaecology
Rheumatology
Epidemiology
Cross-TA
18 cases shown
Visual abstract series for ASCO and ESMO oncology congresses: 18 abstracts transformed into shareable medical infographics
Situation: Text-heavy congress summaries were not being read. MSL teams needed visually immediate formats they could use in field conversations and share with KOLs.
Approach: Designed a systematic visual abstract production pipeline — scientific accuracy review, visual hierarchy design, and audience-specific formatting — for 18 priority abstracts across two major congresses.
Result:Visual abstracts achieved significantly higher engagement than equivalent text-only summaries on internal medical channels.
Biosimilar switching evidence dossier: immunogenicity and efficacy data summary for 6 market access submissions
Situation: Six markets required a robust biosimilar switching evidence package — but immunogenicity and switching data were fragmented across studies with different designs and patient populations.
Approach: Synthesised switching evidence from published and unpublished sources into a single structured dossier — with market-specific supplements for each tender submission format.
Result:The switching dossier was used in all 6 tender submissions — with the biosimilar added to formulary in all 6 markets.
Payer objection handling matrix for CDK4/6 inhibitor: country-specific HTA responses across CEE markets
Situation: Five CEE payer bodies raised different objections to a CDK4/6 inhibitor reimbursement application — no unified framework existed to respond systematically.
Approach: Mapped 42 objection types from published HTA decisions, built structured evidence-backed response pairs for each market, reviewed with local Access leads.
Result:Objection matrices deployed in 4 successful reimbursement submissions within 12 months.
Country-level evidence adaptation for 8 CEE pharma affiliates — one core clinical brief, 8 locally adapted versions
Situation: HQ produced a single global clinical brief. Eight CEE affiliates needed locally relevant versions before the regional launch window closed.
Approach: Built a modular adaptation framework: fixed core content, variable market-specific modules for comparator, reimbursement status, and local terminology.
Result:All 8 markets received adapted materials and launched within the same quarter.
Rapid clinical evidence summary for landmark cardiovascular outcomes trial (CVOT): field-ready within 72 hours of publication
Situation: A landmark CVOT publication would be widely discussed at the next round of KOL meetings. MSL teams needed a field-ready briefing before cardiologists had time to form their own independent interpretation.
Approach: Pre-planned rapid response protocol triggered at publication. Clinical summary, brand-contextualised MSL talking points, and anticipated cardiologist questions assembled and approved within 72 hours.
Result:All field teams received the summary within 72 hours of publication — before the next scheduled KOL meeting cycle.
Delphi expert consensus on postmenopausal hormonal therapy sequencing: 65 authors, published in peer-reviewed journal
Situation: Treatment sequencing in postmenopausal hormonal therapy lacked an international expert consensus — creating inconsistent clinical practice and weakening the evidence base for reimbursement arguments.
Approach: Designed and managed a two-round Delphi consensus process: expert recruitment across multiple countries, structured questionnaire design, statistical analysis of consensus, and full peer-reviewed publication support.
Result:Consensus published in a high-impact gynaecology journal; integrated into 2 national clinical guidelines.
Systematic review and meta-analysis: epidemiology of invasive mycosis in immunocompromised patients
Situation: The epidemiological evidence base for invasive fungal infections in immunocompromised patients was fragmented across heterogeneous studies — making it impossible to present a coherent incidence picture to payers and clinicians.
Approach: Designed and conducted a full systematic review with pre-registered protocol — database searches, screening, data extraction, quality assessment, and meta-analysis — through to peer-reviewed publication.
Result:Published in a peer-reviewed infectious disease journal; widely cited and incorporated into national guideline documents.
Asynchronous digital advisory board for ultra-rare lysosomal storage disorder: platform-based KOL collaboration
Situation: Fewer than 20 specialist physicians globally managed this ultra-rare condition — and their schedules made live advisory board meetings nearly impossible to coordinate.
Approach: Designed an asynchronous digital advisory board using a structured online platform — allowing experts to contribute on their own schedule over a defined 3-week engagement window.
Result:Broad expert alignment achieved without a single live meeting, at 40% lower cost than a conventional advisory board format.
Pharma material approval process optimisation: source verification, slide redesign, and MLR tagging streamlined
Situation: A medical communications team was losing weeks in the MLR approval cycle due to inadequately referenced materials, inconsistent scientific source citation, and slides not meeting approval team standards.
Approach: Audited the existing materials against approval requirements, rebuilt the referencing architecture, redesigned slides to compliance standards, and implemented a systematic MLR tagging workflow.
Result:Approval cycle reduced by an estimated 35% across the material portfolio; team received compliance-ready, fully referenced materials with zero citation errors.
National epidemiological study in rare disease: protocol design through ethics approval, data collection, and peer-reviewed publication
Situation: No national epidemiological data existed for a rare condition in two priority markets — creating an evidence gap that was being used by payer bodies to question the product's unmet need argument.
Approach: Designed and managed the full study lifecycle in both markets: protocol development, ethics submission, site activation, data collection, statistical analysis, manuscript writing, and publication support.
Result:Studies published in peer-reviewed journals in both markets; results are now cited as national epidemiological references.
Patient journey mapping for orphan drug: identifying undiagnosed rare disease patients in fragmented diagnostic systems
Situation: An estimated 60–70% of patients with a rare condition remained undiagnosed — not because diagnosis was impossible, but because no systematic mapping of the diagnostic pathway existed to identify where patients were being lost.
Approach: Conducted structured qualitative research with specialists and GPs, mapped the complete diagnostic journey with quantified drop-off points, and designed a targeted patient-finding algorithm for deployment.
Result:Patient-finding algorithm deployed; previously unidentified patients located across fragmented diagnostic settings.
Pre-launch evidence toolkit for PD-L1 checkpoint inhibitor: MSL deck, payer summary, FAQ, and KOL guide for 4 oncology markets
Situation: With approval 6 weeks away, Medical, Market Access, and Brand teams each had separate material needs — and no shared core story to build from.
Approach: Built from a single core evidence architecture: one shared scientific narrative translated into four audience-specific formats for MSLs, payers, KOLs, and internal teams.
Result:Complete toolkit for 4 markets delivered on time, with all materials aligned to the same core evidence narrative.
Difficult-to-treat rheumatoid arthritis patient identification: AI-powered mining of unstructured EHR clinical data
Situation: A significant proportion of difficult-to-treat RA patients were misclassified as 'standard RA' in EHR systems because the diagnostic criteria relied on unstructured clinical notes rather than coded fields — making them invisible to standard database queries.
Approach: Applied natural language processing to unstructured EHR data — physician notes, treatment records, and lab results — to identify patients meeting difficult-to-treat criteria who had been missed by conventional coding.
Result:Difficult-to-treat RA patients identified from previously inaccessible unstructured data; methodology validated for replication across additional markets and hospital systems.
Advisory board for rare disease specialists: end-to-end scientific event support from slide design to expert consensus report
Situation: A rare disease treatment brand needed to align specialist clinicians — the primary managers of the condition in most markets — on practical management recommendations. No existing forum brought this expert group together across markets.
Approach: Designed and managed a full advisory board for rare disease specialists: scientific programme, participant materials, slide deck, structured facilitation, and a peer-reviewed consensus report delivered within one week of the meeting.
Result:Expert consensus report with actionable management recommendations delivered within 1 week; report adopted by participating specialist departments as internal reference.
Rare disease patient pathway mapping: country-specific diagnostic journey analysis to reduce time to diagnosis
Situation: Patients were waiting an average of 5+ years for a rare disease diagnosis — but the specific points at which the diagnostic system was failing differed by country, making a generic intervention ineffective.
Approach: Conducted country-specific patient pathway research using qualitative physician interviews, patient registry data, and claims database analysis — producing quantified bottleneck profiles for each market.
Result:Country-specific bottleneck profiles delivered; targeted intervention recommendations integrated into the Medical Affairs engagement strategy.
Patient support programme design for rare metabolic condition: expert-informed, multi-country HCP and patient materials
Situation: Patients with a rare metabolic condition faced significant gaps in information and support — and HCPs in non-specialist centres lacked practical guidance on disease management between hospital visits.
Approach: Convened an expert advisory board to define the most critical information gaps, then developed a structured multi-format programme addressing both HCP needs and patient/caregiver needs.
Result:Programme launched across priority markets, equipping HCPs and patients with a cohesive, expert-validated material set.
Global value dossier localised for MENA markets: SGLT2 inhibitor in heart failure — HTA-ready adaptation
Situation: The global value dossier was built for Western HTA bodies. MENA payer bodies had different comparators, different reimbursement criteria, and different expectations for economic evidence.
Approach: Systematically adapted the global dossier for each MENA market — local comparator framing, cost-effectiveness modelling inputs, and HTA submission format requirements.
Result:Positive reimbursement decisions achieved across priority MENA target markets.
Type 1 Diabetes clinical guidelines: international endocrinology guidance adapted to local market access realities
Situation: International T1D clinical guidelines were scientifically strong but too globally framed to serve as practical tools for local market access teams navigating distinct reimbursement environments.
Approach: Mapped each priority market's access landscape, identified the gaps between international guidance and local reimbursement reality, and produced adapted reference documents for each market.
Result:Adapted guidelines adopted as the primary internal reference tool by Market Access teams across all priority markets.
Browse by therapeutic area
TA Portfolios
Have a similar challenge?
Tell us what you’re working on — we’ll show you relevant cases and suggest the fastest path forward.
AI infrastructure
AI-powered.
Expert-validated.
We built AI workflows into our daily practice — not as a marketing claim, but as the infrastructure that lets our medical experts deliver faster without cutting corners.
Research
Structured PubMed queries with narrative or table outputs
Monitoring
Weekly literature digests by drug, target, or topic
AI-Enhanced EDC
Advisory board transcription + structured AI summary
Fact-Checker
Claim verification against your source documents
AI accelerates. Our experts validate.
Every output goes through expert medical review before it reaches your team. AI handles structure and speed — we handle scientific judgement and MLR readiness.
// Query: ribociclib OS data MONALEESA 2023–24
search("ribociclib overall survival", {
years: [2023, 2024],
output: "structured_table"
})
// 847 records → 23 relevant
Processing 847 records...
Evidence Summary
MONALEESA-2 updated OS (NEJM 2023): median OS 63.9 mo vs 51.4 mo (HR 0.76, 95% CI 0.63–0.93). Benefit maintained across all pre-specified subgroups...
SolveLetter · Monthly insights
From the field:
evidence & practice
Advisory Boards
What Makes an Advisory Board Truly Insightful? New Trends, Smarter Ideas, and Next-Gen Formats
An advisory board is one of the most intelligent and powerful tools in the pharma arsenal. With the right event architecture, it helps generate valuable insights and build trust within the medical community.
Jun 2025 · SolveLetter #3
Read →
Evidence Strategy
Why Do RWE and RWD Projects Face Challenges, and How Can We Avoid Them?
With evidence generation becoming a key performance indicator for many medical affairs teams, interest in RWE approaches is growing rapidly. Based on experience across a dozen projects, we’ve gathered insights that might be useful.
Apr 2025 · SolveLetter #2
Read →
KOL Engagement
How to Increase Expert (KOL) Engagement in Congresses, Conferences, and Seminars?
Expert engagement at live events is declining. We explore practical solutions and formats that drive real KOL participation and meaningful scientific dialogue.
Feb 2025 · SolveLetter #1
Read →